Drug intelligence / Profile preview

TFC-837

Development stage: Preclinical
Lead developer: Sirona Biochem

Overview

**TFC-837** is a synthetic and stabilized antifreeze glycoprotein developed by Sirona Biochem for anti-aging and regenerative medicine applications. It protects human fibroblast cells from stressed conditions, including serum deprivation (75% cell survival after 12 days vs. 0% unprotected), UV irradiation, and oxidative stress, by mimicking natural antifreeze glycoproteins to prevent cellular damage.[1][4][13][16] Potential therapeutic uses extend beyond cosmetics to pharmaceutical applications such as extending blood platelet storage, improving cell transplant outcomes, enhancing stem-cell storage, and supporting organ transplantation by mitigating reperfusion injury and stress responses.[1][16]

Other names: anti-aging glycoprotein TFC-837antifreeze glycoprotein TFC-837

Beyond the preview

Go deeper on TFC-837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFC-837.

Explore the full profile